


World Journal of *Stem Cells*

World J Stem Cells 2011 February 26; 3(2): 9-18



Editorial Board

2009-2013

The *World Journal of Stem Cells* Editorial Board consists of 284 members, representing a team of worldwide experts in stem cells research. They are from 28 countries, including Australia (5), Austria (1), Belgium (3), Brazil (2), Canada (7), China (19), Czech Republic (2), Denmark (4), Finland (3), France (5), Germany (14), Hungary (3), India (3), Iran (1), Israel (4), Italy (13), Japan (18), Netherlands (4), Norway (2), Singapore (10), South Korea (15), Spain (6), Sweden (2), Switzerland (3), Turkey (2), United Arab Emirates (1), United Kingdom (15), and United States (117).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Philippe Bourin, *Toulouse*
Andras Dinnyes, *Godollo*
Umberto Galderisi, *Napoli*
Mikhail G Kolonin, *Houston*
Balazs Sarkadi, *Budapest*

GUEST EDITORIAL BOARD MEMBERS

Ing-Ming Chiu, *Miaoli*
Chie-Pein Chen, *Taipei*
Ju Jyh-Cherng, *Taichung*
Hossein Hosseinkhani, *Taipei*
Steven Shoei-Lung Li, *Kasohsiung*
Tzu-Hao Wang, *Tao-Yuan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Jeremy M Crook, *Melbourne*
Alice Pébay, *Victoria*
Kuldip S Sidhu, *Sydney*
Ernst Wolvetang, *Brisbane*
Xin-Fu Zhou, *Adelaide*



Austria

Ludwig Aigner, *Salzburg*



Belgium

Yves Beguin, *Liege*

Mieke Geens, *Brussels*
Najimi Mustapha, *Brussels*



Brazil

Niels Olsen Saraiva Câmara, *São Paulo*
Naiara Zoccal Saraiva, *Jaboticabal*



Canada

Borhane Annabi, *Montreal*
Rosario Isasi, *Quebec*
Xiao-Yan Jiang, *Vancouver*
Seung U Kim, *Vancouver*
Ren-Ke Li, *Toronto*
Jeffrey A Medin, *Toronto*
Kursad Turksen, *Ottawa*



China

Xiu-Wu Bian, *Chongqing*
Yong Dai, *Shenzhen*
Zhong-Chao Han, *Tianjin*
Zhang Hao, *Beijing*
Anskar YH Leung, *Hong Kong*
Gang Li, *Hong Kong*
Gui-Rong Li, *Hong Kong*
Kai-Yan Liu, *Beijing*
Yi-Jia Lou, *Hangzhou*
Xue-Tao Pei, *Beijing*
Jing-He Tan, *Tan-An*
Jin-Fu Wang, *Hangzhou*
Yun-Hai Zhang, *Hefei*



Czech Republic

Petr Dvorak, *Brno*
Jaroslav Mokry, *Hradec Kralove*



Denmark

Basem M Abdallah, *Odense*
Poul Maddox-Hyttel, *Frederiksberg*
Lin Lin, *Tjele*
Soren Paludan Sheikh, *Odense*



Finland

Jukka Partanen, *Helsinki*
Petri Salven, *Helsinki*
Heli Skottman, *Tampere*



France

Alain Chapel, *Paris*
Gwendal Lazennec, *Montpellier*
Muriel Perron, *Paris*
Xavier Thomas, *Lyon*



Germany

James Adjaye, *Berlin*
Christian Buske, *Ulm*
Denis Corbeil, *Dresden*
Frank Edenhofer, *Bonn*
Ursula Margarethe Gehling, *Langen*
Eric Gottwald, *Eggenstein-Leopoldshafen*
Jorg Kleeff, *Munich*
Gesine Kögler, *Düsseldorf*
Nan Ma, *Rostock*
Ulrich Martin, *Hannover*
Heinrich Sauer, *Giessen*
Richard Schäfer, *Tübingen*
Sonja Schrepfer, *Hamburg*
Wolfgang Wagner, *Aachen*

**Hungary**Ferenc Uher, *Budapest***India**Gurudutta U Gangenahalli, *Delhi*
Asok Mukhopadhyay, *New Delhi*
Anjali Suhas Shiras, *Maharashtra***Iran**Masoud Soleimani, *Tehran***Israel**Zeev Blumenfeld, *Haifa*
Rachel Sarig, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*
Shimon Slavin, *Tel Aviv***Italy**Carlo Alberto Beltrami, *Udine*
Clotilde Castaldo, *Naples*
Carmelo Carlo-Stella, *Milano*
Massimo Dominici, *Modena*
Stefania Filos, *Naples*
Angela Gritti, *Milano*
Roberta Morosetti, *Rome*
Felicita Pedata, *Florence*
Anna Chiara Piscaglia, *Rome*
Stefano Pluchino, *Milan*
Caterina AM La Porta, *Milan*
Domenico Ribatti, *Bari***Japan**Tomoki Aoyama, *Kyoto*
Susumu Ikehara, *Osaka*
Taro Matsumoto, *Tokyo*
Yuko Miyagoe-Suzuki, *Tokyo*
Hiroyuki Miyoshi, *Tsukuba*
Takashi Nagasawa, *Kyoto*
Tetsuhiro Niidome, *Kyoto*
Toshio Nikaido, *Toyama*
Kohzo Nakayama, *Nagano*
Tsukasa Ohmori, *Tochigi*
Caterina AM La Porta, *Milan*
Kumiko Saeiki, *Tokyo*
Kazunobu Sawamoto, *Aichi*
Mikiko C Siomi, *Tokyo*
Yoshiaki Sonoda, *Osaka*
Takashi Tada, *Kyoto*
Kotaro Yoshimura, *Tokyo*
Louis Yuge, *Hiroshima***Netherlands**Dirk Gijsbert de Rooij, *Amsterdam*Christine Mummery, *Leiden*
Frank JT Staal, *Leiden*
Marten Piet Smidt, *Utrecht***Norway**Brynjar Foss, *Stavanger*
Berit Bølge Tysnes, *Bergen***Singapore**Yu Cai, *Research Link*
Tong Cao, *Singapore*
Jerry Chan, *Singapore*
Gavin Stewart Dawe, *Medical Drive*
Chan Kwok-Keung Ken, *Singapore*
Chan Woon Khiong, *Singapore*
Steve KW Oh, *Singapore*
Seeram Ramakrishna, *Singapore*
Herbert Schwarz, *Singapore*
Shu Wang, *Biopolis Way***South Korea**Jong Wook Chang, *Seoul*
Chong-Su Cho, *Seoul*
Ssang-Goo Cho, *Seoul*
Ho Jae Han, *Gwangju*
Ki-Chul Hwang, *Seoul*
Kyung-Sun Kang, *Seoul*
Haekwon Kim, *Seoul*
Hoeon Kim, *Daejeon*
Mee Kum Kim, *Seoul*
Yoon Jun Kim, *Seoul*
Soo-Hong Lee, *Seoul*
Dae-Sik Lim, *Daejeon*
Byung Soon Park, *Seoul*
Sun U Song, *Incheon*
Seung Kwon You, *Seoul***Spain**Fernando Cobo, *Granada*
Sabrina C Desbordes, *Barcelona*
Marta Muñoz Llamosas, *España*
Maria P De Miguel, *Madrid*
María Dolores Miñana, *Valencia*
Felipe Prosper, *Navarra***Sweden**M Quamrul Islam, *Linköping*
Stefan Karlsson, *Lund***Switzerland**Thomas Daikeler, *Basel*
Sabrina Mattoli, *Basel*
Arnaud Scherberich, *Basel***Turkey**Alp CAN, *Ankara*
Berna Arda, *Ankara***United Arab Emirates**Sherif M Karam, *Al-Ain***United Kingdom**Dominique Bonnet, *London*
Kristin Mary Braun, *London*
Wei Cui, *London*
David C Hay, *Edinburgh*
Wael Kafienah, *Bristol*
Francis L Martin, *Lancaster*
Mike Modo, *London*
Donald Palmer, *London*
Dame Julia Polak, *London*
James Alexander Ross, *Edinburgh*
Alastair James Sloan, *Cardiff*
Virginie Sottile, *Nottingham*
Hong Wan, *London*
He-Ping Xu, *Aberdeen*
Rike Zietlow, *Cardiff***United States**Gregor Barr Adams, *Los Angeles*
Kinji Asahina, *Los Angeles*
Craig S Atwood, *Madison*
Debabrata Banerjee, *New Brunswick*
Aline M Betancourt, *New Orleans*
Surinder Kumar Batra, *Omaha*
Bruce Alan Bunnell, *New Orleans*
Jason A Burdick, *Philadelphia*
Anthony WS Chan, *Atlanta*
Rebecca J Chan, *Indianapolis*
G Rasul Chaudhry, *Rochester*
Jonathan Donald Chesnut, *Carlsbad*
Herman S Cheung, *Coral Gables*
Kent W Christopherson II, *Chicago*
David Wade Clapp, *Indianapolis*
Rubin Clinton, *New York*
Claudius Conrad, *Boston*
Charles Samuel Cox, *Houston*
Marcos de Lima, *Houston*
Douglas C Dean, *Louisville*
Goberdhan Dimri, *Evanston*
David Dingli, *Rochester*
Fu-Liang Du, *Vernon*
Todd Evans, *New York*
Toshihiko Ezashi, *Columbia*
Vincent Falanga, *Alternate*
Ira J Fox, *Pittsburgh*
Markus Frank, *Boston*
Sanga Gehmert, *Houston*
Yong-Jian Geng, *Houston*
Joseph C Glorioso, *Pittsburgh*
Kristbjorn Orri Gudmundsson, *Frederick*
Yan-Lin Guo, *Hattiesburg*
Tong-Chuan He, *Chicago*
Lorraine Iacovitti, *Philadelphia*
Kunlin Jin, *Novato*

Michael R King, *Ithaca*
Uma Lakshmi pathy, *Carlsbad*
Hillard Michael Lazarus, *Shaker Heights*
Techung Lee, *Buffalo*
Robert C Miller, *Rochester*
Tao-Sheng Li, *Los Angeles*
Xiao-Nan Li, *Houston*
Ching-Shwun Lin, *San Francisco*
P Charles Lin, *Nashville*
Su-Ling Liu, *Ann Arbor*
Aurelio Lorico, *Las Vegas*
Jean-Pierre Louboutin, *Philadelphia*
Bing-Wei Lu, *Stanford*
Qing Richard Lu, *Dallas*
Nadya L Lumelsky, *Bethesda*
Hong-Bo R Luo, *Boston*
Hinh Ly, *Atlanta*
Teng Ma, *Tallahassee*
Kenneth Maiese, *Detroit*
Robert L Mauck, *Philadelphia*
Glenn Edwards Mcgee, *New York*
Murielle Mimeault, *Omaha*
Guo-Li Ming, *Baltimore*
Masato Nakafuku, *Cincinnati*
Christopher Niyibizi, *Hershey*
Seh-Hoon Oh, *Gainesville*
Frank Pajonk, *Los Angeles*

Gregory M Pastores, *New York*
Derek A Persons, *Memphis*
Donald G Phinney, *Florida*
Donald George Phinney, *New Orleans*
Dimitris G Placantonakis, *New York*
George E Plopper, *Troy*
Derek Radisky, *Jacksonville*
Murugan Ramalingam, *Gaithersburg*
Pranela Rameshwar, *Newark*
Jeremy N Rich, *Cleveland*
Angie Rizzino, *Omaha*
Paul Ronald Sanberg, *Tampa*
Gerald Phillip Schatten, *Pittsburgh*
Ashok Kumar Shetty, *Durham*
Igor I Slukvin, *Madison*
Shay Soker, *Winston-Salem*
Hong-Jun Song, *Baltimore*
Kenichi Tamama, *Columbus*
Dean G Tang, *Smithville*
Hugh S Taylor, *New Haven*
Jonathan L Tilly, *Boston*
Jakub Tolar, *Minneapolis*
Deryl Troyer, *Manhattan*
Scheffer Chuei-Goong Tseng, *Miami*
Lyuba Varticovski, *Bethesda*
Tandis Vazin, *Berkeley*
Kent E Vrana, *Hershey*

Lyuba Varticovski, *Bethesda*
Qi Wan, *Reno*
Charles Wang, *Los Angeles*
Guo-Shun Wang, *New Orleans*
Zack Z Wang, *Scarborough*
David Warburton, *Los Angeles*
Li-Na Wei, *Jackson Hall*
Andre Van Wijnen, *Worcester*
Marc Adrian Williams, *Rochester*
Joseph C Wu, *Stanford*
Li-Zi Wu, *Gainesville*
Sean M Wu, *Boston*
Yan Xu, *Pittsburgh*
Jun Yan, *Louisville*
Jing Yang, *Orange*
Li-Jun Yang, *Florida*
Phillip Chung-Ming Yang, *Stanford*
Pampee Paul Young, *Nashville*
Hong Yu, *Miami*
Seong-Woon Yu, *East Lansing*
Xian-Min Zeng, *Novato*
Bao-Hong Zhang, *Greenville*
Ying Zhang, *Baltimore*
Xue-Sheng Zheng, *Massachusetts*
X Long Zheng, *Philadelphia*
John F Zhong, *Los Angeles*



World Journal of Stem Cells

Contents

Monthly Volume 3 Number 2 February 26, 2011

EDITORIAL

- 9 Progenitor cells as remote "bioreactors": Neuroprotection *via* modulation of the systemic inflammatory response

Walker PA, Letourneau PA, Bedi S, Shah SK, Jimenez F, Cox CS Jr

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Stem Cells*

APPENDIX I Meetings
 I-V Instructions to authors

ABOUT COVER Walker PA, Letourneau PA, Bedi S, Shah SK, Jimenez F, Cox CS Jr. Progenitor cells as remote "bioreactors": Neuroprotection via modulation of the systemic inflammatory response.
World J Stem Cells 2011; 3(2): 9-18
<http://www.wjgnet.com/1948-0210/full/v3/i2/9.htm>

AIM AND SCOPE *World Journal of Stem Cells* (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a Monthly open-access peer-reviewed journal supported by an editorial board consisting of 284 experts in stem cell research from 28 countries.
 The major task of *WJSC* is to rapidly report original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including embryonic stem cells, neural stem cells, hematopoietic stem cells, mesenchymal stem cells, tissue-specific stem cells, cancer stem cells, the stem cell niche, stem cell genomics and proteomics, and translational and clinical research. In a word, papers published in *WJSC* will cover the biology, culture, and differentiation of stem cells from all stages of development from germ cell to embryo and adult.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Na Liu*
Responsible Electronic Editor: *Wen-Hua Ma*
Proofing Editor-in-Chief: *Lian-Sheng Ma*
Responsible Science Editor: *Jin-Lei Wang*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Stem Cells

LAUNCH DATE
 December 31, 2009

SPONSOR
 Beijing Baishideng BioMed Scientific Co., Ltd.,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1892
 Fax: 0086-10-8538-1893
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING
 Editorial Board of *World Journal of Stem Cells*,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: +0086-10-8538-1891
 Fax: +0086-10-8538-1893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
 Baishideng Publishing Group Co., Limited,
 Room 1701, 17/F, Henan Bulding,
 No.90 Jaffe Road, Wanchai,
 Hong Kong, China
 Fax: 00852-3115-8812

Telephone: 00852-5804-2046
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
 Beijing Baishideng BioMed Scientific Co., Ltd.,
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1892
 Fax: 0086-10-8538-1893
 E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

ONLINE SUBSCRIPTION
 One-Year Price 108.00 USD

PUBLICATION DATE
 February 26, 2011

CSSN
 ISSN 1948-0210 (online)

PRESIDENT AND EDITOR-IN-CHIEF
 Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
 Philippe Bourin, *Toulouse*
 Andras Dinnyes, *Godollo*
 Umberto Galderisi, *Napoli*
 Mikhail G Kolonin, *Houston*
 Balazs Sarkadi, *Budapest*

EDITORIAL OFFICE
 Jin-Lei Wang, Director
World Journal of Stem Cells
 Room 903, Building D, Ocean International Center,
 No. 62 Dongsihuan Zhonglu, Chaoyang District,
 Beijing 100025, China
 Telephone: 0086-10-8538-1891
 Fax: 0086-10-8538-1893
 E-mail: wjsc@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
 © 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-0210office>

Progenitor cells as remote "bioreactors": Neuroprotection *via* modulation of the systemic inflammatory response

Peter A Walker, Phillip A Letourneau, Supinder Bedi, Shinil K Shah, Fernando Jimenez, Charles S Cox Jr

Peter A Walker, Phillip A Letourneau, Shinil K Shah, Charles S Cox Jr, Department of Surgery, University of Texas Medical School at Houston, Houston, TX 77030, United States
Peter A Walker, Supinder Bedi, Shinil K Shah, Fernando Jimenez, Charles S Cox Jr, Department of Pediatric Surgery, University of Texas Medical School at Houston, Houston, TX 77030, United States

Shinil K Shah, Charles S Cox Jr, Michael E DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, Texas A & M University, College Station, TX 77840, United States

Author contributions: Walker PA, Letourneau PA, Bedi S, Shah SK, Jimenez F and Cox CS Jr wrote this editorial together. **Supported by** Grants NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation

Correspondence to: Charles S Cox Jr, MD, Department of Pediatric Surgery, University of Texas Medical School at Houston, 6431 Fannin Street, MSB 5.236, Houston, TX 77030, United States. charles.s.cox@uth.tmc.edu

Telephone: +1-713-5007307 Fax: +1-713-5007296

Received: May 19, 2010 Revised: January 5, 2011

Accepted: January 12, 2011

Published online: February 26, 2011

Abstract

Acute central nervous system (CNS) injuries such as spinal cord injury, traumatic brain injury, autoimmune encephalomyelitis, and ischemic stroke are associated with significant morbidity, mortality, and health care costs worldwide. Preliminary research has shown potential neuroprotection associated with adult tissue derived stem/progenitor cell based therapies. While initial research indicated that engraftment and transdifferentiation into neural cells could explain the observed benefit, the exact mechanism remains controversial. A second hypothesis details localized stem/progenitor cell engraftment with alteration of the loco-regional milieu; however, the limited rate of cell engraftment makes this theory less likely. There is a growing amount of pre-

clinical data supporting the idea that, after intravenous injection, stem/progenitor cells interact with immunologic cells located in organ systems distant to the CNS, thereby altering the systemic immunologic/inflammatory response. Such distant cell "bioreactors" could modulate the observed post-injury pro-inflammatory environment and lead to neuroprotection. In this review, we discuss the current literature detailing the above mechanisms of action for adult stem/progenitor cell based therapies in the CNS.

© 2011 Baishideng. All rights reserved.

Key words: Traumatic brain injury; Cerebral stroke; Spinal cord injury; Stem cells; Bone marrow; Inflammation

Peer reviewers: Angela Gritti, PhD, San Raffaele Telethon Institute for Gene Therapy, San Raffaele Scientific Institute, Via Olgettina, 58 -20132 Milano, Italy; Ludwig Aigner, PhD, Professor, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

Walker PA, Letourneau PA, Bedi S, Shah SK, Jimenez F, Cox CS Jr. Progenitor cells as remote "bioreactors": Neuroprotection via modulation of the systemic inflammatory response. *World J Stem Cells* 2011; 3(2): 9-18 Available from: URL: <http://www.wjgnet.com/1948-0210/full/v3/i2/9.htm> DOI: <http://dx.doi.org/10.4252/wjsc.v3.i2.9>

INTRODUCTION

Acute central nervous system (CNS) injuries such as spinal cord injury (SCI), traumatic brain injury (TBI), and ischemic stroke are associated with significant worldwide morbidity and mortality. Up to 5 million people are burdened by the morbidity associated with TBI annually with approximately 40% of patients reporting unmet needs 1 year after injury^[1]. In addition, an initial cerebrovascular accident is associated with a lifelong loss of 9.5

quality adjusted life years^[2]. Overall, the combined economic impact of SCI, TBI, and ischemic stroke surpasses several billion dollars annually in the United States^[3,4].

Early preclinical research has shown potential benefit from adult tissue progenitor cell therapy for acute and chronic CNS injury. Adult tissue stem/progenitor cells are maintained in select microenvironments or niches throughout the body. Within the niche, stem cell proliferation, depletion, and involvement in resident tissue regeneration and repair is tightly regulated^[5]. Stem/progenitor cells are prime candidates for novel therapies due to their observed capacity for self renewal and ability to differentiate down multiple cell lines^[6].

Preliminary *in vivo* and *in vitro* research has shown potential benefit associated with stem/progenitor cell therapy after TBI^[7], ischemic stroke^[8], and SCI^[9]. While initial research indicated that engraftment and transdifferentiation into neural cells could explain the observed benefit^[10], the exact mechanism remains controversial. A second hypothesis details localized stem/progenitor cell engraftment with alteration of the loco-regional milieu; however, the limited rate of cell engraftment makes this theory less likely. There is a growing amount of preclinical data supporting the idea that, after intravenous injection, stem/progenitor cells interact with immunologic cells located in organ systems distant to the CNS thereby altering the systemic immunologic/inflammatory response. Such distant cell “bioreactors” could modulate the observed post-injury pro-inflammatory environment and lead to neuroprotection.

ENGRAFTMENT AND TRANSDIFFERENTIATION

Early preclinical research hypothesized that transplanted bone marrow-derived mesenchymal stromal cells (MSCs) could migrate and engraft at the site of injury and adopt neuronal cell markers indicating their differentiation into neurons [neuronal nuclei (NeuN)] and astrocytes [glial fibrillary acidic protein (GFAP)]^[11]. Additional work completed by Hayase *et al.*^[12] showed induction of neurospheres from MSCs *in vitro*. The neurospheres were then implanted into rodent cerebral cortex after focal ischemic injury and remained engrafted at the injury site for up to 100 d. The engrafted progenitor cells displayed neural markers with a concordant improvement in animal behavioral recovery^[12]. Using a rodent spinal cord injury model, the Ha laboratory implanted human umbilical cord blood mononuclear cells (HUCBCs) into the injury region and found engrafted HUCBCs up to 8 wk after injury. HUCBCs were found to express the neural markers GFAP and microtubule-associated protein 2 (MAP2). Functional improvement via locomotor testing was observed in the animals for up to 8 wk^[13].

Such preliminary work investigating the intravenous infusion of MSCs has been promising. However, much debate remains about the frequency and clinical signifi-

cance of progenitor cell “transdifferentiation” and the validity of neural marker expression with most investigators believing this to be erroneous^[14-16]. Coyne *et al.*^[17] showed that MSCs labeled with BrdU transferred their label to replicating neurons and gave the erroneous impression that MSCs were expressing these proteins when double labels were used. In addition, hematopoietic stem cells (HSCs) implanted into a spinal cord injury site^[18] and murine striatum^[16] failed to transdifferentiate into neurons and actually showed differentiation into macrophages and microglia. Furthermore, Hunt *et al.*^[19] observed the failure of transdifferentiation with collagen deposition and axonal injury after the implantation of MSCs into demyelinated spinal cord.

Additional *in vitro* research has been carried out to investigate the capacity for stem/progenitor cell transdifferentiation into neurons. Barnabe *et al.*^[20] have shown that MSCs could be chemically induced to produce the neuronal proteins NF-200, S100, β -tubulin III, NSE and MAP-2; however, the cells had an apoptotic rate greater than 50%. *In vitro* electrophysiological recordings did not show neuronal properties as no sodium / potassium gradients or action potentials were observed^[20]. Further research has shown that bone marrow derived multipotent adult progenitor cells (MAPCs) express the neural proteins β III tubulin and NF200 at baseline. Culture of MAPCs in neural differentiation media failed to upregulate protein expression, indicating that the appearance of neural transdifferentiation based upon neural antigen expression can be misleading^[21]. While preliminary work pointed towards transdifferentiation as a potential mechanism for cognitive improvement, a large body of preclinical research now indicates that this is an unlikely pathway towards functional benefit.

MODULATION OF THE LOCO-REGIONAL INFLAMMATORY RESPONSE

The observed functional benefit observed with intravenous stem/progenitor cell therapy could be secondary to localized engraftment and interaction with resident microglia leading to modulation of the loco-regional milieu. Work completed in the Cox laboratory measured the concentration of the pro-inflammatory cytokines interleukin (IL)-1 α , IL-1 β , IL-6, and tumor necrosis factor (TNF)- α , found in cortical tissue after TBI in a rodent model. A multiplex cytokine assay showed an increase in all of the measured pro-inflammatory cytokines measured (IL-1 α , IL-1 β , IL-6, and TNF- α) in the direct injury and penumbra areas of the injured brain as shown in Figure 1^[22]. These results detail the post injury pro-inflammatory response and identify a potential target for novel therapies.

Early *in vitro* work investigated the co-culture of human immunologic cells with MSCs and showed an increase in production of the anti-inflammatory cytokines IL-4 and IL-10 in accordance with a decrease in production of the pro inflammatory cytokine interferon γ (IFN- γ).




Figure 1 Elevated intracerebral cytokines identified in specific areas and at specific time points relative to the traumatic brain injury. The proinflammatory cytokines interleukin (IL)-1 α (A), IL-1 β (B), IL-6 (C), and tumor necrosis factor- α (D) were significantly elevated 6 h after CCI in the injury and penumbral regions when compared with sham animals ($^bP < 0.01$ for all). IL-1 α , IL-1 β , and IL-6 remained elevated through 12, 12 and 24 h, respectively ($^bP < 0.01$ or $^aP < 0.05$). In the frontal area, IL-6 was significantly increased at 24 h (33- to 50-fold; $P < 0.01$; Dunnett's test), but not at 6 or 12 h after traumatic brain injury. Reproduced with permission^[22].

Additionally, an increase in T regulatory cell (a known mediator of the anti-inflammatory response) differentiation was observed^[23]. Walker *et al.*^[24] found an increase in the cytokine interleukin 6 (IL-6) in rodent brain tissue supernatant after the direct intrathecal implantation of MSCs using a TBI model. To explore the potential mechanisms of action, a series of *in vitro* MSC and neuronal stem cell (NSC) co-culture experiments was devised. Direct contact co-culture led to activation of the NSC NF κ B pathway with a concordant decrease in NSC apoptosis which was not replicated in transwell (non contact) cultures, indicating the need for direct MSC/NSC contact for effect^[24]. Additional work investigating the direct intracerebral implantation of MSCs using a stroke model found increased intracerebral IL-10 with a corresponding decrease in TNF- α production. The observed modulation of the loco-regional milieu led to functional improvement^[25]. Pluchino *et al.*^[26] have shown that the intravenous delivery of neurosphere-derived stem/progenitor cells in a chronic CNS inflammatory model leads to the engraftment of cells in perivascular niches. Upon engraftment, the neurosphere-derived cells induce apoptosis in circulating blood born T cells thereby decreasing the amount of inflammatory neuronal injury^[26]. Such preliminary work has shown a potential mechanism to explain the observed benefit;

however, the majority of studies are based upon the direct intracerebral or intrathecal implantation of progenitor cells.

A potential barrier to the direct implantation of stem/progenitor cells is related to the size or the multifocality of the lesion. A significant injury cavity can occur after TBI, SCI, or ischemic stroke that could potentially require multiple stereotactic injections (needle tracts) which could exacerbate the inflammatory response to injury. More commonly, there are multiple foci of diffuse injury that would make stereotactic implantation impractical. In order to circumvent the need for multiple injections, alternate delivery methods such as intravenous injection need to be considered.

The intravenous delivery of stem/progenitor cells is an attractive subject to the potential for widespread distribution and the lack of invasiveness from the procedure. Biodistribution studies completed by Fischer *et al.*^[27] have shown that the vast majority of injected progenitor cells remain sequestered in the lungs, as illustrated in Figure 2, and have described this as a significant pulmonary first pass effect^[27]. These findings have been replicated by many investigators with Harting *et al.*^[28] showing only 0.001% of intravenously transplanted cells engrafted in the brain parenchyma with significant sequestration of




Figure 2 Fluorescent imaging of QDOT (green) labeled mesenchymal stromal cells, neuronal stem cells, multipotent adult progenitor cells, and bone marrow mononuclear cells after intravenous injection. Less than 1% of mesenchymal stromal cells (MSCs) bypassed the lungs into the arterial circulation (as shown by high levels of green fluorescence). A two fold increase in pulmonary bypass was observed with neuronal stem cells (NSCs) and multipotent adult progenitor cells (MAPCs) with a 50 fold increase observed with bone marrow mononuclear cells (BMMCs). Reproduced with permission^[48].

MSCs in the lung up to 3 d after injection. Additionally, Lee *et al.*^[29] found significant pulmonary sequestration with only 0.001% of intravenously injected MSCs in any distant organ system.

The observed significant pulmonary first pass effect greatly decreases the number of stem/progenitor cells that reach the systemic circulation, thereby limiting the quantity that could interact with the injury area and engraft. It is possible that only a few MSCs are needed to activate resident microglia leading to modulation of the local regional inflammatory/immunologic response. However, emerging data indicates that the hypothesis of stem/progenitor cells acting as local “bio-reactors” seems more unlikely and requires further investigation.

MODULATION OF THE SYSTEMIC INFLAMMATORY RESPONSE

The intravenous delivery of stem/progenitor cells remains the ideal delivery vehicle due to the potential for widespread distribution and simplicity although cell delivery is limited by a significant pulmonary first pass effect. Despite the limited number of cells reaching the systemic circulation, multiple investigators have reported neuroprotection with intravenous therapy^[30,31]. Such results indicate that it may not be necessary for a large number of cells to reach the injury zone to produce effect. It is also possible that the stem/progenitor cells are interacting with immunologic cells in remote organ systems and acting as distant “bioreactors” which alter the systemic inflammatory/immunologic response and lead to the observed benefit. The possible locations of remote progenitor/immunologic cell interactions include the lung, spleen, liver, lymph nodes, and kidney.

Pulmonary immunologic cells

Secondary to the significant pulmonary first pass effect, the majority of stem/progenitor cells are sequestered within the lung after intravenous injection, indicating a high probability of interaction between the transplanted cells and resident pulmonary immunologic cells^[27]. Mei *et al.*^[32] found a reduction in lipopolysaccharide (LPS)-induced pulmonary inflammation after the intravenous injection of MSCs in a murine acute lung injury model. A further reduction in alveolar inflammation and permeability was observed when the MSCs were transfected with vasculoprotective gene angiopoietin 1 (ANGPT1) prior to injection. A reduction in neutrophils as well as the pro inflammatory cytokines IFN- γ , TNF- α , IL-6 and IL-1 β was found with both treatment groups^[32].

A recent study completed in the Mezey laboratory investigated the effect of intravenous MSC therapy on systemic inflammation due to sepsis using a murine cecal ligation and puncture (CLP) model. This seminal study characterized the cellular interactions between MSCs and lung-derived monocytes/macrophages. MSC treatment improved survival, organ function and reduced pro-inflammatory cytokines (TNF- α and IL-6) in the serum,

as shown in Figure 3. The injected MSCs were found to directly interact with pulmonary macrophages resulting in an increase in serum levels of IL-10, which is produced by monocytes and macrophages^[33] and associated with a reduction in the migration of neutrophils^[34] and decreased oxidative damage^[35]. The role of IL-10 production in the observed improvement in mortality and end organ function was confirmed via a series of experiments using IL-10 knockout mice and IL-10 receptor antibodies as shown in Figure 4. Furthermore, a series of *in vitro* and *in vivo* experiments was completed showing that MSC derived prostaglandin E₂ production stimulated resident macrophages to produce IL-10 *via* activation through EP2 and EP4 receptors^[36].


These preliminary studies have shown the potential importance of interactions between transplanted stem/progenitor cells and pulmonary macrophages. The observed interaction appears to modulate both the local and systemic inflammatory response increasing anti-inflammatory cytokine production which could lead to enhanced neuroprotection.

Interaction with splenocytes

Recent work completed in the Pennypacker laboratory has shown the release of immunologic T cells from the spleen into the systemic circulation with a concordant reduction in splenic mass after ischemic stroke in a rodent model. Adrenergic output appeared to mitigate this effect as treatment with the pan adrenergic blocker, carvediol, reversed the observed loss in splenic mass and reduced stroke cavity volume^[37]. Vendrame *et al.*^[38] showed that the observed reduction in splenic mass associated with ischemic stroke was likely due to the release of cytotoxic CD8+ T cells which could contribute to the secondary injury seen after stroke. Injection of HUCBCs 24 h after ischemic stroke restored splenic mass, secondary to the retention of the splenocyte derived cytotoxic T cells. Results also showed a reduction in injury cavity volume as well as an increase in IL-10 and decreases in the pro inflammatory cytokines TNF- α and INF- γ ^[38].

Similar work carried out by Schwarting *et al.*^[39] using a rodent ischemic stroke model has shown increased levels of the pro-inflammatory cytokines TNF- α and IL-1 β in the serum as well as chemokine receptor 2 and CX3CR1 within splenocytes. After intravenous injection, HSCs were found primarily in the spleen with levels of TNF- α , IL-1 β , CX3CR1, and chemokine receptor 2 towards sham levels. A reduction in microglial activation and macrophage infiltration was also observed in the peri-injury parenchyma with a concordant decrease in injury cavity volume and neuronal cell apoptosis^[39].

Lee *et al.*^[40] have investigated the role of NSC therapy for the treatment of intracerebral hemorrhage in a rodent model. The intravenous injection of human NSCs 2 h after injury was associated with improved functional outcomes and decreased cerebral edema as well as decreased intracerebral inflammatory infiltration and neuronal apoptosis. In addition, a reduction in the pro inflammatory cytokines TNF- α and IL-6 was measured in the






Figure 3 Effect of intravenous injection of BMSCs on the course of sepsis after cecal ligation and puncture. A: Survival curves of mice after cecal ligation and puncture (CLP) and a variety of treatments using BMSCs from C57/BL6, FVB/NJ and BALB/c mice, as well as C57/BL6-derived fibroblasts; B: BMSC treatment effects on kidney function, as reflected by serum concentration of creatinine (SCr). The number of mice in all measurements is as follows: sham, $n = 5$; CLP, $n = 13$; CLP + BMSC, $n = 14$. Tubular injury scores are shown at right; C: Intense PAS staining of hepatocytes is shown after sham operation and BMSC treatment. No staining can be seen in CLP. After treatment (CLP + BMSC), the red staining by PAS in hepatocytes indicates partial glycogen storage capacity. Scale bar, 20 μm ; D: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations in the liver after sham and BMSC, CLP or CLP and BMSC treatment; E: Serum amylase concentrations after sham and BMSC, CLP or CLP and BMSC treatment; F: DAB staining of caspase-3 cells in untreated spleen sections and BMSC-treated spleen sections. A quantitative comparison between the numbers of apoptotic splenic cells in treated versus untreated mice (right) shows a significant decrease with BMSC treatment. Scale bar, 100 μm ; G: Serum tumor necrosis factor (TNF)- α and interleukin (IL)-6 concentrations after sham and BMSC, CLP or CLP and BMSC treatment; H: Serum IL-10 concentrations at 3, 6 and 12 h after CLP. $n = 8$ -11 at each time point. Error bars represent means \pm SE; ^a $P < 0.05$; ^b $P < 0.01$. Reproduced with permission^[36].




Figure 4 Fate of injected BMSCs and effect of BMSC treatment on survival of normal and immune cell-depleted mice. A-C Immunohistochemical staining

showing that BMSCs pre-labeled with Q-dot (red punctate staining; (A) travel to the lung (B) and take up residence in close proximity to macrophages (C); The latter cells were immunostained with an antibody to Iba1 (ionized calcium-binding adaptor molecule-1, a specific marker of the macrophage lineage⁴⁷) and visualized with Alexa-Fluor-488 conjugated to a secondary antibody (green). Scale bar, 10 μ m; (D-F) Summary of the effectiveness of BMSC treatment of mice genetically lacking or depleted of certain subsets of immune cells or soluble mediators. Survival curves show survival percentage of macrophage-depleted mice with or without BMSC treatment (D), survival percentage of BMSC-treated CLP mice and untreated mice after neutralizing IL-10 or blocking the IL-10 receptor (e) and survival percentage of after treatment with BMSCs derived from Il10^{-/-} septic mice (F). **P* < 0.05. Reproduced with permission^[36].

brain and spleen. Histology completed to track the NSCs showed very few to be engrafted in the cortical tissue; however, a higher number of NSCs were found in the marginal zone of the spleen. Further experiments completed with a non-specific cell line (fibroblasts) or with rats after splenectomy failed to show functional benefit or decreased edema, thereby confirming the need for the splenocyte/progenitor cell interaction to obtain the observed immunomodulation^[40].

These data represent a growing field of research into the role of the spleen in post injury inflammation and the ways that progenitor cells may modulate that response. In stroke models, progenitor cell therapy has been shown to preserve splenic mass and modulate the inflammatory response. More studies are required to further investigate the mechanism of immunomodulation in order to optimize the timing and dosage for cell delivery.

Other distant organ systems

The Uccelli laboratory recently completed a series of *in vivo* and *in vitro* experiments to investigate the potential role of MSCs in a murine experimental autoimmune encephalomyelitis (EAE) model. Co-culture of MSCs and T cells inhibited T cell proliferation with a concordant decrease in TNF- α and IFN γ production. The intravenous injection of MSCs in the murine encephalomyelitis model showed MSC engraftment in the lymphoid tissue and a decrease in the autoimmune response secondary to T cell unresponsiveness^[41]. Additional work carried out by Kassis *et al*^[42] using a similar model showed engraftment in lymphoid tissue associated with a decrease in both mortality and CNS inflammation as well as protection of the resident axons.

Research completed by Refei *et al*^[43] using a murine EAE model showed a decrease in spinal cord CD4+ T cell infiltration associated with the amelioration of symptoms after the intraperitoneal injection of MSCs. The observed benefit is secondary to the inhibition of CD4+ T cell activation via suppression of STAT3 phosphorylation by MSC-derived CCL2^[43].

There is limited data on the interaction of implanted adult stem/progenitor cells with other organ systems in the setting of neurological injury. Distribution studies have demonstrated stem/progenitor cells to engraft in the liver and kidney as well as the lung and spleen^[44-47]. At the time of this review, there is no published data on the liver and/or kidney acting as potential bioreactors to modulate the systemic inflammatory or immune response.

CONCLUSION

Preliminary research has shown the potential benefit of

adult tissue stem/progenitor cell therapy for a wide array of acute and chronic CNS injuries. While initial work indicated that the transdifferentiation of stem/progenitor cells into new neurons could account for the observed neuroprotection, the frequency of CNS engraftment and clinical significance of transdifferentiation remains controversial. A growing amount of evidence supports the idea that injected stem/progenitor cells interact with distant organ systems and immunologic cells leading to modulation of the systemic inflammatory response. Multiple investigators have shown a decrease in the pro-inflammatory response to injury which could account for the observed neuroprotection. Such promising work should stimulate the design of additional pre-clinical experiments to further outline the therapeutic mechanism prior to implementation of clinical trials.

REFERENCES

- 1 **Thompson HJ.** A critical analysis of measures of caregiver and family functioning following traumatic brain injury. *J Neurosci Nurs* 2009; **41**: 148-158
- 2 **Lee HY, Hwang JS, Jeng JS, Wang JD.** Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. *Stroke* 2010; **41**: 739-744
- 3 **Faul M, Wald MM, Rutland-Brown W, Sullivent EE, Sattin RW.** Using a cost-benefit analysis to estimate outcomes of a clinical treatment guideline: testing the Brain Trauma Foundation guidelines for the treatment of severe traumatic brain injury. *J Trauma* 2007; **63**: 1271-1278
- 4 **Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF.** Lifetime cost of stroke in the United States. *Stroke* 1996; **27**: 1459-1466
- 5 **Scadden DT.** The stem-cell niche as an entity of action. *Nature* 2006; **441**: 1075-1079
- 6 **Weiner LP.** Definitions and criteria for stem cells. *Methods Mol Biol* 2008; **438**: 3-8
- 7 **Qu C, Mahmood A, Lu D, Goussev A, Xiong Y, Chopp M.** Treatment of traumatic brain injury in mice with marrow stromal cells. *Brain Res* 2008; **1208**: 234-239
- 8 **de Vasconcelos Dos Santos A, da Costa Reis J, Diaz Paredes B, Moraes L, Jasmin, Giraldo-Guimarães A, Mendez-Otero R.** Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in rats. *Brain Res* 2010; **1306**: 149-158
- 9 **Jung DI, Ha J, Kang BT, Kim JW, Quan FS, Lee JH, Woo EJ, Park HM.** A comparison of autologous and allogenic bone marrow-derived mesenchymal stem cell transplantation in canine spinal cord injury. *J Neurol Sci* 2009; **285**: 67-77
- 10 **Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC.** Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. *Exp Neurol* 2002; **174**: 11-20
- 11 **Lu D, Mahmood A, Wang L, Li Y, Lu M, Chopp M.** Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. *Neuroreport* 2001; **12**: 559-563

- 12 **Hayase M**, Kitada M, Wakao S, Itokazu Y, Nozaki K, Hashimoto N, Takagi Y, Dezawa M. Committed neural progenitor cells derived from genetically modified bone marrow stromal cells ameliorate deficits in a rat model of stroke. *J Cereb Blood Flow Metab* 2009; **29**: 1409-1420
- 13 **Kuh SU**, Cho YE, Yoon DH, Kim KN, Ha Y. Functional recovery after human umbilical cord blood cells transplantation with brain-derived neutrophilic factor into the spinal cord injured rat. *Acta Neurochir (Wien)* 2005; **147**: 985-92; discussion 992
- 14 **Castro RF**, Jackson KA, Goodell MA, Robertson CS, Liu H, Shine HD. Failure of bone marrow cells to transdifferentiate into neural cells in vivo. *Science* 2002; **297**: 1299
- 15 **Wagers AJ**, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. *Science* 2002; **297**: 2256-2259
- 16 **Roybon L**, Ma Z, Asztely F, Fosum A, Jacobsen SE, Brundin P, Li JY. Failure of transdifferentiation of adult hematopoietic stem cells into neurons. *Stem Cells* 2006; **24**: 1594-1604
- 17 **Coyne TM**, Marcus AJ, Woodbury D, Black IB. Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. *Stem Cells* 2006; **24**: 2483-2492
- 18 **Kim KN**, Oh SH, Lee KH, Yoon DH. Effect of human mesenchymal stem cell transplantation combined with growth factor infusion in the repair of injured spinal cord. *Acta Neurochir Suppl* 2006; **99**: 133-136
- 19 **Hunt DP**, Irvine KA, Webber DJ, Compston DA, Blakemore WF, Chandran S. Effects of direct transplantation of multipotent mesenchymal stromal/stem cells into the demyelinated spinal cord. *Cell Transplant* 2008; **17**: 865-873
- 20 **Barnabé GF**, Schwindt TT, Calcagnotto ME, Motta FL, Martinez G Jr, de Oliveira AC, Keim LM, D'Almeida V, Mendez-Otero R, Mello LE. Chemically-induced RAT mesenchymal stem cells adopt molecular properties of neuronal-like cells but do not have basic neuronal functional properties. *PLoS One* 2009; **4**: e5222
- 21 **Raedt R**, Pinxteren J, Van Dycke A, Waeytens A, Craeye D, Timmermans F, Vonck K, Vandekerckhove B, Plum J, Boon P. Differentiation assays of bone marrow-derived Multipotent Adult Progenitor Cell (MAPC)-like cells towards neural cells cannot depend on morphology and a limited set of neural markers. *Exp Neurol* 2007; **203**: 542-554
- 22 **Harting MT**, Jimenez F, Adams SD, Mercer DW, Cox CS Jr. Acute, regional inflammatory response after traumatic brain injury: Implications for cellular therapy. *Surgery* 2008; **144**: 803-813
- 23 **Aggarwal S**, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; **105**: 1815-1822
- 24 **Walker PA**, Harting MT, Jimenez F, Shah SK, Pati S, Dash PK, Cox CS Jr. Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFkappaB-mediated increase in interleukin-6 production. *Stem Cells Dev* 2010; **19**: 867-876
- 25 **Liu N**, Chen R, Du H, Wang J, Zhang Y, Wen J. Expression of IL-10 and TNF-alpha in rats with cerebral infarction after transplantation with mesenchymal stem cells. *Cell Mol Immunol* 2009; **6**: 207-213
- 26 **Pluchino S**, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, Martinello M, Cattalini A, Bergami A, Furlan R, Comi G, Constantin G, Martino G. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. *Nature* 2005; **436**: 266-271
- 27 **Fischer UM**, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev* 2009; **18**: 683-692
- 28 **Harting MT**, Jimenez F, Xue H, Fischer UM, Baumgartner J, Dash PK, Cox CS. Intravenous mesenchymal stem cell therapy for traumatic brain injury. *J Neurosurg* 2009; **110**: 1189-1197
- 29 **Lee RH**, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* 2009; **5**: 54-63
- 30 **Lu D**, Sanberg PR, Mahmood A, Li Y, Wang L, Sanchez-Ramos J, Chopp M. Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury. *Cell Transplant* 2002; **11**: 275-281
- 31 **Mahmood A**, Lu D, Chopp M. Intravenous administration of marrow stromal cells (MSCs) increases the expression of growth factors in rat brain after traumatic brain injury. *J Neurotrauma* 2004; **21**: 33-39
- 32 **Mei SH**, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. *PLoS Med* 2007; **4**: e269
- 33 **Moore KW**, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. *Annu Rev Immunol* 1993; **11**: 165-190
- 34 **Bonder CS**, Norman MU, Macrae T, Mangan PR, Weaver CT, Bullard DC, McCafferty DM, Kubes P. P-selectin can support both Th1 and Th2 lymphocyte rolling in the intestinal microvasculature. *Am J Pathol* 2005; **167**: 1647-1660
- 35 **Hernandez LA**, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia-reperfusion-induced microvascular injury. *Am J Physiol* 1987; **253**: H699-703
- 36 **Németh K**, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009; **15**: 42-49
- 37 **Ajmo CT Jr**, Collier LA, Leonardo CC, Hall AA, Green SM, Womble TA, Cuevas J, Willing AE, Pennypacker KR. Blockade of adrenoceptors inhibits the splenic response to stroke. *Exp Neurol* 2009; **218**: 47-55
- 38 **Vendrame M**, Gemma C, Pennypacker KR, Bickford PC, Davis Sanberg C, Sanberg PR, Willing AE. Cord blood rescues stroke-induced changes in splenocyte phenotype and function. *Exp Neurol* 2006; **199**: 191-200
- 39 **Schwartz S**, Litwak S, Hao W, Bähr M, Weise J, Neumann H. Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. *Stroke* 2008; **39**: 2867-2875
- 40 **Lee ST**, Chu K, Jung KH, Kim SJ, Kim DH, Kang KM, Hong NH, Kim JH, Ban JJ, Park HK, Kim SU, Park CG, Lee SK, Kim M, Roh JK. Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke. *Brain* 2008; **131**: 616-629
- 41 **Zappia E**, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. *Blood* 2005; **106**: 1755-1761
- 42 **Kassis I**, Grigoriadis N, Gowda-Kurkalli B, Mizrahi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. *Arch Neurol* 2008; **65**: 753-761
- 43 **Rafei M**, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, Yuan S, Young YK, Boivin MN, Forner K, Basik M, Galipeau J. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. *J Immunol* 2009; **182**: 5994-6002
- 44 **Yoon JK**, Park BN, Shim WY, Shin JY, Lee G, Ahn YH. In vivo tracking of ¹¹¹In-labeled bone marrow mesenchymal

- stem cells in acute brain trauma model. *Nucl Med Biol* 2010; **37**: 381-388
- 45 **Detante O**, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C, Jaillard A, Hommel M, Ghezzi C, Remy C. Intravenous administration of ^{99m}Tc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. *Cell Transplant* 2009; **18**: 1369-1379
- 46 **Vilalta M**, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging. *Stem Cells Dev* 2008; **17**: 993-1003
- 47 **Kang SK**, Shin MJ, Jung JS, Kim YG, Kim CH. Autologous adipose tissue-derived stromal cells for treatment of spinal cord injury. *Stem Cells Dev* 2006; **15**: 583-594
- 48 **Fischer UM**, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. *Stem Cells Dev* 2009; **18**: 683-692

S- Editor Wang JL L- Editor Hughes D E- Editor Ma WH

Acknowledgments to reviewers of *World Journal of Stem Cells*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Stem Cells*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Ludwig Aigner, PhD, Professor, Institute of Molecular Regenerative Medicine, Paracelsus Medical University, Strubergasse 21, A-5020 Salzburg, Austria

Borhane Annabi, PhD, Professor, Department of Chemistry, Biomed Research Centre, Université du Québec à Montréal Montreal, Quebec, H2X 2J6, Canada

Denis Corbeil, PhD, Tissue Engineering Laboratories, Biotec, Medical Faculty, Technical University of Dresden, Tatzberg 47-49, 01307, Dresden, Germany

Yusuke Furukawa, MD, PhD, Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

Mieke Geens, PhD, EMGE, UZ Brussel, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium

Zhong-Chao Han, MD, PhD, Professor, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

Xiao-Yan Jiang, MD, PhD, Associate Professor, Medical Genetics, University of British Columbia, Senior Scientist, Terry Fox Laboratory, BC Cancer Agency Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada

Hiroyuki Miyoshi, PhD, Subteam for Manipulation of Cell Fate, BioResourceCenter, RIKEN, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan

Alice Pébay, PhD, Centre for Neuroscience & Department of Pharmacology, University of Melbourne, Parkville VIC 3010, Australia

Soren Paludan Sheikh, MD, PhD, Professor, Department of Biochemistry, Pharmacology and Genetics, Odense University Hospital, University of Southern Denmark, Sdr. Boulevard 29, DK 5000, Denmark

Heli Teija Kristiina Skottman, PhD, Academy of Finland Research fellow, Regea Institute for Regenerative medicine, University of Tampere, Finland, Biokatu 12, 33520 Tampere, Finland

Andre Van Wijnen, PhD, Department of Cell Biology, Rm S3-322, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States

Hong Yu, PhD, Miami VA Health Care System, 1201 NW 16th St, Research 151, Miami, FL 33125, United States

John F Zhong, PhD, Assistant Professor, School of Medicine, University of Southern California, 2025 Zonal Ave, RMR 210, Los Angeles, CA 90033, United States

Meetings

Events Calendar 2011

February 26, 2011
 Stem Cell Agency Governance
 Subcommittee Meeting, Crowne
 Plaza SFO, 1177 Airport Blvd,
 Burlingame, CA,
 United States

January 29-February 2, 2011
 LabAutomation2011,
 Palm Springs, CA, United States

February 4, 2011
 7th annual Swiss Stem Cell Network
 meeting, Swiss Federal Institute

of Technology in Lausanne,
 Switzerland

March 1, 2011
 The 6th Annual Stem Cell Summit,
 11 Fulton Street, New York City, NY,
 United States

March 22, 2011
 StemCONN 2011, Farmington, CT,
 United States

March 27-31, 2011
 SBS 17th Annual Conference and
 Exhibition, Orlando, FL, United States

April 6-8, 2011
 EMBO Conference-Advances in
 Stem Cell Research: Development,
 Regeneration and Disease,
 Institut Pasteur, Paris,
 France

April 7-10, 2011
 2011 CSHL Meeting on Stem Cell
 Engineering & Cell Therapy, Cold
 Spring Harbor Laboratory, Cold
 Spring Harbor, NY, United States

April 25-26, 2011
 International Conference on Stem
 Cell Research, Hotel Equatorial
 Penang, Malaysia

April 27, 2011
 6th Annual Wisconsin Stem Cell
 Symposium, BioPharmaceutical
 Technology Center, Madison, WI,
 United States


May 9-11, 2011
 The World Stem Cells and
 Regenerative Medicine Congress
 2011, Victoria Park Plaza, London,
 United Kingdom

May 23-24, 2011
 The 4th Annual Israeli Stem Cell
 Meeting, Beit Sourasky,
 Chaim Sheba Medical Center,
 Israel

May 26-27, 2011
 7th annual Stem Cell Research &
 Therapeutics Conference, Boston,
 MA, United States

September 20-24, 2011
 2011 CSHL Meeting on Stem
 Cell Biology, Cold Spring
 Harbor Laboratory, Cold Spring
 Harbor, NY, United States

October 2011
 3rd Annual World Stem Cells &
 Regenerative Medicine
 Congress Asia 2011, Seoul,
 South Korea



Instructions to authors

GENERAL INFORMATION

World Journal of Stem Cells (*World J Stem Cells*, *WJSC*, online ISSN 1948-0210, DOI: 10.4252), is a monthly, open-access (OA), peer-reviewed journal supported by an editorial board of 284 experts in stem cell from 28 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJSC* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJSC* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJSC* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an

open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJSC* is to report rapidly original articles and comprehensive reviews on basic laboratory investigations of stem cells and their application in clinical care and treatment of patients. *WJSC* is designed to cover all aspects of stem cells, including: Embryonic, neural, hematopoietic, mesenchymal, tissue-specific, and cancer stem cells; the stem cell niche; stem cell genomics and proteomics; and stem cell techniques and their application in clinical trials. Papers published in *WJSC* will cover the biology, culture, differentiation and application of stem cells from all stages of their development, from germ cell to embryo and adult.

Columns

The columns in the issues of *WJSC* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in stem cells; (9) Brief Articles: To briefly report the novel and innovative findings in stem cells; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJSC*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of stem cells; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in stem cells.

Name of journal

World Journal of Stem Cells

CSSN

ISSN 1948-0210 (online)

Indexed and Abstracted in

PubMed Central, PubMed

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Riddit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJSC* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/1948-0210office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/1948-0210/g_info_20100313165700.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjsc@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George

Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJSC*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the

main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at http://www.wjgnet.com/1948-0210/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ... *etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

Instructions to authors

PMID and DOI

Pleased provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *v* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172144.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindIII*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

Editorial: http://www.wjgnet.com/1948-0210/g_info_20100313165833.htm

Frontier: http://www.wjgnet.com/1948-0210/g_info_20100313170509.htm

Topic highlight: http://www.wjgnet.com/1948-0210/g_info_20100313170618.htm

Observation: http://www.wjgnet.com/1948-0210/g_info_20100313170727.htm

Guidelines for basic research: http://www.wjgnet.com/1948-0210/g_info_20100313170855.htm

Guidelines for clinical practice: http://www.wjgnet.com/1948-0210/g_info_20100313171012.htm

Review: http://www.wjgnet.com/1948-0210/g_info_20100313171124.htm

Original articles: http://www.wjgnet.com/1948-0210/g_info_20100313171239.htm

Brief articles: http://www.wjgnet.com/1948-0210/g_info_20100313171358.htm

Case report: http://www.wjgnet.com/1948-0210/g_info_20100313171504.htm

Letters to the editor: http://www.wjgnet.com/1948-0210/g_info_20100313171613.htm

Book reviews: http://www.wjgnet.com/1948-0210/g_info_20100313171713.htm

Guidelines: http://www.wjgnet.com/1948-0210/g_info_20100313171803.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJSC*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office**World Journal of Stem Cells**

Editorial Department: Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China

E-mail: wjsc@wjgnet.com

<http://www.wjgnet.com>

Telephone: +86-10-85381891

Fax: +86-10-85381893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/1948-0210/g_info_20100313172045.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/1948-0210/g_info_20100313172000.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJSC will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJSC is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.